Prevail Therapeutics Inc (PRVL)
Prevail Therapeutics is a gene therapy company using discoveries in human genetics with the goal of developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. Co.'s lead program is PR001 for the treatment of Parkinson's disease with GBA1 mutation, and neuronopathic (Type 2 or Type 3) Gaucher disease. Co. is focused on developing a pipeline of gene therapies for a range of neurodegenerative diseases, including PR006 for the treatment of frontotemporal dementia with GRN mutation, or FTD-GRN, and PR004 for the treatment of synucleinopathies.
Quotes delayed 20 minutes